购物车
- 全部删除
- 您的购物车当前为空
CCR6 antagonist 1 是一种 CCR6 拮抗剂,可抑制 CCL20/CCR6 信号通路。 CCR6 antagonist 1 可用于自身免疫介导的炎症性疾病的研究,如炎症性肠病 (IBDs)。
为众多的药物研发团队赋能,
让新药发现更简单!
CCR6 antagonist 1 是一种 CCR6 拮抗剂,可抑制 CCL20/CCR6 信号通路。 CCR6 antagonist 1 可用于自身免疫介导的炎症性疾病的研究,如炎症性肠病 (IBDs)。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 269 | 现货 | |
2 mg | ¥ 378 | 现货 | |
5 mg | ¥ 596 | 现货 | |
10 mg | ¥ 928 | 现货 | |
25 mg | ¥ 1,930 | 现货 | |
50 mg | ¥ 2,790 | 现货 | |
100 mg | ¥ 4,180 | 现货 | |
500 mg | ¥ 8,890 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 657 | 现货 |
产品描述 | CCR6 antagonist 1, a chemical compound acting as a CCR6 antagonist, effectively inhibits the CCL20/CCR6 axis. Its utility lies in research focused on autoimmune-mediated inflammatory diseases, including inflammatory bowel diseases (IBDs). |
体外活性 | CCR6 antagonist 1 (50 μM, 3 h) blocks the CCL20-induced CD4+ T cell migration. CCR6 antagonist 1 (30 nM-300 μM, 20 min) inhibits miniGi recruitment to CCR6 induced by CCL20, and β-arrestin-1 recruitment to CCR6 and CCR5 by CCL20 and CCL5 (5 nM), respectively[1]. |
体内活性 | CCR6 antagonist 1 (1 mg/kg, s.c., twice daily for 3 days) alleviates TNBS-induced inflammatory responses in mice. CCR6 antagonist 1 (1 mg/kg, s.c., twice, before and after zymosan treatment) shows anti-inflammatory effects in Zymosan-induced peritonitis mice[1]. |
分子量 | 319.28 |
分子式 | C17H12F3NO2 |
CAS No. | 588674-64-0 |
Smiles | Cc1c(oc2ccccc12)C(=O)Nc1ccc(cc1)C(F)(F)F |
密度 | 1.358 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 90 mg/mL (281.9 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容